Xamiol®, a new treatment in scalp psoriasis: short- and long-term results;Un nouveau traitement dans le psoriasis du cuir chevelu : XXamio ®l : ŔResultats court terme et́ a long terme

Annales de Dermatologie et de Venereologie

Volumn 136, Issue SUPPL. 3, 2009, Pages 546-550

  Cambazard, F ^a  

^a HÔPITAL NORD   (France)

Author keywords

Betamethasone; Calcipotriol; Efficacy; Long term; Psoriasis; Scalp; Tolerance

Indexed keywords

BETAMETHASONE; BETAMETHASONE DIPROPIONATE; CALCIPOTRIOL; UNCLASSIFIED DRUG; XAMIOL;

ACUTE DRUG ADMINISTRATION; ADULT; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; SCALP; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 68149171729     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.annder.2008.09.025     Document Type: Article

References (2)

1. ®) in the treatment of psoriasis vulgaris Br J Dermatol 154 2006 1155 1160 (Pubitemid 43727399)
2. K. Kragballe, J. Austad, L. Barnes, A. Bibby, M. de la Brassinne, and F. Cambazard Efficacy results of a 52-week, randomised, doubleblind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris Dermatology 213 2006 319 326 (Pubitemid 44837020)